Study Complete
Sponsor ID
20130296
Chart Review of Repatha® in subjects with HyperlipidaemiaHEYMANS
Study Details
Review of clinical characteristics of patients who are prescribed Repatha® and how their treatment is managed.
Protocol Summary
Primary Outcome Measures
Description of clinical characteristics of subjects initiated on Repatha®
Timeframe: Study day 1
Secondary Outcome Measures
Describe LDL-C and other cholesterol values over time
Timeframe: Up to 26 weeks prior to the first dose of Repatha®, up to 30 months post first dose of Repatha®
Describe Repatha® dose over time
Timeframe: From the first dose of Repatha® up to 30 months post first dose
Describe use of other lipid-modifying therapies
Timeframe: From the first dose of Repatha® up to 30 months post first dose
Describe Physician visits
Timeframe: From the first dose of Repatha® up to 30 months post first dose
Describe hospitalizations
Timeframe: From the first dose of Repatha® up to 30 months post first dose
Describe Repatha® dose frequency over time
Timeframe: From the first dose of Repatha® up to 30 months post first dose
Describe Repatha® administrative device use over time
Timeframe: From the first dose of Repatha® up to 30 months post first dose
Locations
Location
Research Site
Wien, Austria, 1060
Status
Recruiting
Location
Research Site
Göteborg, Sweden, 413 45
Status
Completed
Location
Research Site
Malmo, Sweden, 205 02
Status
Completed
Location
Research Site
Stockholm, Sweden, 141 86
Status
Recruiting
Location
Research Site
Feldkirch, Austria, 6800
Status
Recruiting
Location
Research Site
Pirna, Germany, 01796
Status
Recruiting
Showing {first} - {last} of {total} Results